[go: up one dir, main page]

CY1105119T1 - Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων - Google Patents

Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων

Info

Publication number
CY1105119T1
CY1105119T1 CY20061101067T CY061101067T CY1105119T1 CY 1105119 T1 CY1105119 T1 CY 1105119T1 CY 20061101067 T CY20061101067 T CY 20061101067T CY 061101067 T CY061101067 T CY 061101067T CY 1105119 T1 CY1105119 T1 CY 1105119T1
Authority
CY
Cyprus
Prior art keywords
fatty acids
polyunsaturated fatty
cardiovascular events
primary prevention
serious cardiovascular
Prior art date
Application number
CY20061101067T
Other languages
English (en)
Inventor
Hajime Shibuya
Original Assignee
Pro Aparts - Investimentos E Consultoria Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105119(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pro Aparts - Investimentos E Consultoria Lda filed Critical Pro Aparts - Investimentos E Consultoria Lda
Publication of CY1105119T1 publication Critical patent/CY1105119T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Περιγράφεται η χρήση πολυακόρεστων λιπαρών οξέων της σειράς ω -3 όπως του εικοσαπεντενοϊκού οξέως (EPA, C20:5 ω-3), του εικοσιδυοεξενοϊκού οξέως (DHA, C22:6 ω-3) ή των φαρμακευτικά αποδεκτών παραγώγων τους για την πρωτογενή πρόληψη σοβαρών καρδιαγγειακών επεισοδίων σε άτομα τα οποία δεν έχουν υποστεί προηγουμένως επεισόδια εμφράγματος.
CY20061101067T 2001-11-12 2006-07-31 Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων CY1105119T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI002384A ITMI20012384A1 (it) 2001-11-12 2001-11-12 Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori

Publications (1)

Publication Number Publication Date
CY1105119T1 true CY1105119T1 (el) 2009-11-04

Family

ID=11448595

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101067T CY1105119T1 (el) 2001-11-12 2006-07-31 Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων

Country Status (10)

Country Link
US (4) US20030100610A1 (el)
EP (1) EP1310249B1 (el)
JP (1) JP4731789B2 (el)
AT (1) ATE331510T1 (el)
CY (1) CY1105119T1 (el)
DE (1) DE60212786T2 (el)
DK (1) DK1310249T3 (el)
ES (1) ES2262741T3 (el)
IT (1) ITMI20012384A1 (el)
PT (1) PT1310249E (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
KR101255650B1 (ko) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 새로운 ｄｈａ 유도체 및 약제로서의 용도
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US8367725B2 (en) 2005-07-08 2013-02-05 Mochida Pharmaceutical Co., Ltd. Composition and/or method for preventing onset and/or recurrence of cardiovascular events
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
US7652068B2 (en) * 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US20110166228A1 (en) 2006-11-01 2011-07-07 Anne Kristin Holmeide Composition
WO2008053331A1 (en) 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).
US20100266681A1 (en) * 2006-11-03 2010-10-21 Anne Kristin Holmeide Fatty acid alcohols
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
RS53694B1 (en) 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. LONG-TERM TREATMENT OF SYMPTOMATIC HEART INSUFFICIENCY
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
SMT202000078T1 (it) 2009-02-10 2020-03-13 Amarin Pharmaceuticals Ie Ltd Estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
AU2014203034B2 (en) * 2009-04-29 2016-09-15 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
KR101343249B1 (ko) 2009-04-29 2013-12-19 아마린 파마, 인크. 안정한 제약 조성물 및 그의 사용 방법
RU2489145C1 (ru) 2009-04-29 2013-08-10 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способ их применения
RU2519043C2 (ru) * 2009-06-15 2014-06-10 Амарин Фарма, Инк. Композиции и способы понижения уровня триглицеридов без повышения уровня хс-лпнп у субъекта, получающего сопутствующую терапию
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
JP5827625B2 (ja) * 2009-10-29 2015-12-02 アカスティ ファーマ インコーポレイテッド 濃縮治療用リン脂質組成物
CA2792090C (en) * 2010-03-04 2019-05-14 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CA2826663A1 (en) * 2011-02-07 2012-08-16 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
US20120302639A1 (en) 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
CA2827579A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
WO2012112517A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20140191573A1 (en) * 2011-09-24 2014-07-10 Kool Koncepts Limited Energy management system
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
GEP201706768B (en) 2012-06-29 2017-11-10 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014011895A2 (en) * 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN109562186B (zh) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 与专门促消退介质的盐有关的组合物和方法
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
AU2018317802B2 (en) 2017-08-15 2024-04-04 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
EP4009961A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Solubility enhancement of poorly soluble actives
EP4009956A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Down streaming process for the production of polyunsaturated fatty acid salts
US20230037453A1 (en) * 2020-04-01 2023-02-09 Evonik Operations Gmbh Preparation for use as vasorelaxant
EP4125438A1 (en) * 2020-04-01 2023-02-08 Evonik Operations GmbH Preparation for use as antioxidant
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2679997B2 (ja) 1986-10-15 1997-11-19 株式会社日立製作所 直流遮断器
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4918104A (en) * 1987-06-16 1990-04-17 Weiss Howard S Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH0225447A (ja) 1988-07-13 1990-01-26 Nippon Oil & Fats Co Ltd 高度不飽和脂肪酸類の製造方法
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
GB9125602D0 (en) * 1991-12-02 1992-01-29 Efamol Holdings Method of preventing reocclusion of arteries
CN1082909A (zh) 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06263634A (ja) * 1993-03-10 1994-09-20 Sagami Chem Res Center カルシウム拮抗薬
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5541225A (en) * 1994-10-11 1996-07-30 The General Hospital Corporation α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia
NL9401743A (nl) * 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
DE69625616T3 (de) * 1995-11-28 2010-07-08 B. Braun Melsungen Ag Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JPH10139664A (ja) * 1996-11-12 1998-05-26 Sagami Chem Res Center 抗不整脈薬
JPH11239464A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 運動時の危険因子除去能を有する組成物
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
DE60022987T2 (de) * 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP4337273B2 (ja) * 2001-04-20 2009-09-30 日本水産株式会社 基礎代謝増進剤
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
AU784852B2 (en) * 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Also Published As

Publication number Publication date
US20080269331A1 (en) 2008-10-30
US7553870B2 (en) 2009-06-30
ITMI20012384A1 (it) 2003-05-12
DE60212786D1 (de) 2006-08-10
DE60212786T2 (de) 2007-06-28
PT1310249E (pt) 2006-09-29
ES2262741T3 (es) 2006-12-01
US20100016428A1 (en) 2010-01-21
JP2003146874A (ja) 2003-05-21
EP1310249B1 (en) 2006-06-28
US20040162349A1 (en) 2004-08-19
EP1310249A1 (en) 2003-05-14
US20030100610A1 (en) 2003-05-29
JP4731789B2 (ja) 2011-07-27
ATE331510T1 (de) 2006-07-15
US8648061B2 (en) 2014-02-11
DK1310249T3 (da) 2006-09-25
US7619002B2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
CY1105119T1 (el) Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων
DK1152755T3 (da) Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde
NO991635D0 (no) Farmas°ytisk preparat omfattende eikospentaensyre og/eller stearidonsyre
HK1058883A1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders.
DK1157692T3 (da) Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
AU2003238240A1 (en) ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
DK1121115T3 (da) PUFA-tilskud
HK1059386A1 (en) Potentiation of therapeutic effects of polyunsaturated fatty acids
NO20026093L (no) Terapeutiske kombinasjoner av fettsyrer
EP1698685A4 (en) FAT COMPOSITION
BRPI0512528A (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
CA2481220A1 (en) Dietary methods for canine performance enhancement
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
NO20014341L (no) Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger
RU93049092A (ru) Лечение жирными кислотами
DE60329588D1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen
TW360545B (en) Dermatologic preparation
EP4327870A3 (en) Method for improving white matter integrity in hyperphenylalaninemia and phenylketonuria patients
DK1296669T3 (da) Kombinationspræparat af omega-3 fedtsyrer og konjugerede linoliesyrer til behandling af immunologisk prægede sygdomsbilleder